21世纪经济报道记者唐唯珂报道 ICL+CRO的跨界并购又有新故事。 2024年11月13日,国内第三方医学检验艾迪康控股有限公司抛出公告:其全资附属公司拟以2.04亿美元(约合15亿元人民币)收购JSR Life Sciences所持冠科生物100%股权。 华南某中型券商分析师向21世纪经济报道记者表示,这起典型的"ICL+ CRO"跨界并购,不仅标志着艾迪康从单一诊断服务商向全球一体化...
Source Link21世纪经济报道记者唐唯珂报道 ICL+CRO的跨界并购又有新故事。 2024年11月13日,国内第三方医学检验艾迪康控股有限公司抛出公告:其全资附属公司拟以2.04亿美元(约合15亿元人民币)收购JSR Life Sciences所持冠科生物100%股权。 华南某中型券商分析师向21世纪经济报道记者表示,这起典型的"ICL+ CRO"跨界并购,不仅标志着艾迪康从单一诊断服务商向全球一体化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.